{"id":381664,"date":"2020-11-16T08:03:49","date_gmt":"2020-11-16T13:03:49","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381664"},"modified":"2020-11-16T08:03:49","modified_gmt":"2020-11-16T13:03:49","slug":"astellas-to-present-new-data-on-gilteritinib-in-flt3-mutation-positive-acute-myeloid-leukemia-at-the-2020-american-society-of-hematology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/astellas-to-present-new-data-on-gilteritinib-in-flt3-mutation-positive-acute-myeloid-leukemia-at-the-2020-american-society-of-hematology-annual-meeting\/","title":{"rendered":"Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual Meeting"},"content":{"rendered":"
\n

Includes five oral presentations that collectively explore the use of gilteritinib across the FLT3mut+ AML care continuum<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TOKYO<\/span>, Nov. 16, 2020<\/span> \/PRNewswire\/ —\u00a0Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa<\/span>, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the virtual 62nd<\/sup> American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 5-8, 2020<\/span>.<\/p>\n

\n

\n
\n \"Astellas
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Nine Astellas-sponsored abstracts focused on patients with AML with a positive FLT3 mutation (FLT3mut+) are being presented, comprising five oral presentations, three posters and one online-only presentation. Oral presentations include new data on the use of gilteritinib, either as monotherapy or in combination, across the FLT3mut+ AML patient spectrum \u2013 from those newly diagnosed, to relapsed or refractory patients who have been pre-treated with other tyrosine kinase inhibitors (TKIs) \u2013 as well as a secondary analysis of the Phase 3 ADMIRAL trial.\u00a0\u00a0<\/p>\n

“The research being presented at ASH will shed light on critical unmet needs and continuing progress against AML, which remains a hard-to-treat cancer in spite of continuing medical advances,” said Andrew Krivoshik<\/span>, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. “Several presentations will describe the effects of gilteritinib in a wide range of AML patients with a positive FLT3 mutation. We also look forward to discussing our Phase 3 LACEWING trial in progress, as well as findings from the STREAMLINE study related to real-world FLT3 testing rates in AML patients, both upon diagnosis and after relapse.”<\/p>\n

Gilteritinib is approved as XOSPATA\u00ae<\/sup><\/b>\u00a0in the U.S. and selected other countries for the treatment of adult patients who have relapsed or refractory FLT3mut+ AML.<\/p>\n

\n Oral Presentations<\/b>\n <\/p>\n

\n Title:<\/b>\u00a0A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results (Abstract 24)<\/a><\/p>\n